Which fracture risks are risedronate sodium 5 mg film-coated tablets in the Aspire Pharma Ltd product indicated to reduce in postmenopausal osteoporosis?

Risedronate sodium 5 mg film-coated tablets (Aspire Pharma Ltd product) are indicated to reduce vertebral fracture risk in postmenopausal osteoporosis and hip fracture risk in established postmenopausal osteoporosis.